Rhythm Pharmaceuticals Stock Price To Earning

RYTM Stock  USD 59.92  0.02  0.03%   
Rhythm Pharmaceuticals fundamentals help investors to digest information that contributes to Rhythm Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Rhythm Stock. The fundamental analysis module provides a way to measure Rhythm Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rhythm Pharmaceuticals stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Rhythm Pharmaceuticals Company Price To Earning Analysis

Rhythm Pharmaceuticals' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

P/E

 = 

Market Value Per Share

Earnings Per Share

More About Price To Earning | All Equity Analysis

Rhythm Price To Earning Driver Correlations

Understanding the fundamental principles of building solid financial models for Rhythm Pharmaceuticals is extremely important. It helps to project a fair market value of Rhythm Stock properly, considering its historical fundamentals such as Price To Earning. Since Rhythm Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Rhythm Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Rhythm Pharmaceuticals' interrelated accounts and indicators.
0.95-0.8-0.790.80.970.41.00.420.980.860.320.790.85-0.720.770.820.920.81-0.23
0.95-0.77-0.650.840.950.150.960.390.950.760.520.710.82-0.810.80.860.860.66-0.13
-0.8-0.770.74-0.53-0.66-0.32-0.79-0.49-0.74-0.77-0.18-0.77-0.680.56-0.63-0.63-0.73-0.750.18
-0.79-0.650.74-0.48-0.73-0.78-0.77-0.45-0.76-0.980.03-0.93-0.760.52-0.63-0.59-0.8-0.980.69
0.80.84-0.53-0.480.840.130.820.190.840.60.540.610.62-0.670.860.830.780.48-0.11
0.970.95-0.66-0.730.840.370.970.410.980.830.370.730.82-0.730.760.860.920.74-0.27
0.40.15-0.32-0.780.130.370.380.220.360.71-0.490.620.35-0.060.20.270.530.76-0.78
1.00.96-0.79-0.770.820.970.380.410.990.850.350.780.85-0.730.780.830.920.79-0.22
0.420.39-0.49-0.450.190.410.220.410.440.46-0.040.450.33-0.190.340.340.420.47-0.2
0.980.95-0.74-0.760.840.980.360.990.440.850.380.780.83-0.720.790.80.880.76-0.26
0.860.76-0.77-0.980.60.830.710.850.460.850.080.930.8-0.610.70.70.860.95-0.65
0.320.52-0.180.030.540.37-0.490.35-0.040.380.080.080.53-0.780.50.290.13-0.090.25
0.790.71-0.77-0.930.610.730.620.780.450.780.930.080.7-0.520.820.670.790.94-0.54
0.850.82-0.68-0.760.620.820.350.850.330.830.80.530.7-0.90.690.570.730.74-0.31
-0.72-0.810.560.52-0.67-0.73-0.06-0.73-0.19-0.72-0.61-0.78-0.52-0.9-0.69-0.62-0.62-0.470.18
0.770.8-0.63-0.630.860.760.20.780.340.790.70.50.820.69-0.690.730.720.65-0.22
0.820.86-0.63-0.590.830.860.270.830.340.80.70.290.670.57-0.620.730.920.61-0.21
0.920.86-0.73-0.80.780.920.530.920.420.880.860.130.790.73-0.620.720.920.82-0.37
0.810.66-0.75-0.980.480.740.760.790.470.760.95-0.090.940.74-0.470.650.610.82-0.57
-0.23-0.130.180.69-0.11-0.27-0.78-0.22-0.2-0.26-0.650.25-0.54-0.310.18-0.22-0.21-0.37-0.57
Click cells to compare fundamentals
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Competition

Rhythm Retained Earnings

Retained Earnings

(850 Million)

Rhythm Pharmaceuticals reported last year Retained Earnings of (894.74 Million)
Based on the latest financial disclosure, Rhythm Pharmaceuticals has a Price To Earning of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earning for all United States stocks is 100.0% higher than that of the company.

Rhythm Price To Earning Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rhythm Pharmaceuticals' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rhythm Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rhythm Pharmaceuticals by comparing valuation metrics of similar companies.
Rhythm Pharmaceuticals is currently under evaluation in price to earning category among its peers.

Rhythm Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Rhythm Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Rhythm Pharmaceuticals' managers, analysts, and investors.
Environmental
Governance
Social

Rhythm Fundamentals

About Rhythm Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Rhythm Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rhythm Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rhythm Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Rhythm Pharmaceuticals is a strong investment it is important to analyze Rhythm Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rhythm Pharmaceuticals' future performance. For an informed investment choice regarding Rhythm Stock, refer to the following important reports:
Check out Rhythm Pharmaceuticals Piotroski F Score and Rhythm Pharmaceuticals Altman Z Score analysis.
To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.32)
Revenue Per Share
1.863
Quarterly Revenue Growth
0.478
Return On Assets
(0.46)
Return On Equity
(1.48)
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.